skip to Main Content

Adding Adjuvant Erlotinib to Gemcitabine After R0 Resection of Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The German phase III CONKO-005 trial has shown no significant benefit of adding adjuvant erlotinib (Tarceva) to gemcitabine after R0 resection in patients with pancreatic ductal adenocarcinoma. The findings were reported in the Journal of Clinical Oncology by Sinn et al.
Read more . . . 

Back To Top